Article
Orthopedics
Zhiwei Luan, Yansong Wang
Summary: This study investigated the association between ankylosing spondylitis (AS) and m6A methylation. By analyzing 72 samples from the GSE73754 dataset, AS-related m6A genes were identified and found to be negatively correlated with the incidence of AS. The study also suggested a potential relationship between AS and immunity, providing further insights into AS treatment.
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
(2023)
Article
Immunology
Yuting Chen, Ye Wu, Lanlan Fang, Hui Zhao, Shenqian Xu, Zongwen Shuai, Haiyang Yu, Guoqi Cai, He-Qin Zhan, Faming Pan
Summary: The role of m6A modification in ankylosing spondylitis (AS) was investigated in this study. The researchers found that m6A modification was decreased in T cells of AS patients, and this abnormal modification was attributed to the downregulation of METTL14. METTL14 played a critical role in regulating autophagy activity and inflammation by targeting FOXO3a. These findings highlight the importance of m6A methylation mechanisms in the regulation of autophagy and inflammation, providing insights for the development of therapeutic strategies for AS.
CLINICAL IMMUNOLOGY
(2023)
Article
Immunology
Zena Chen, Xuqi Zheng, Xinyu Wu, Jialing Wu, Xiaomin Li, Qiujing Wei, Xi Zhang, Linkai Fang, Ou Jin, Jieruo Gu
Summary: The study found that the gut microbiome was significantly restored in AS patients after adalimumab therapy, with a higher abundance of Comamonas in non-responders compared to responders, although no statistical difference was observed. These results suggest the potential of gut microbiome as biomarkers for therapeutic evaluation.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Rheumatology
Michael Nissen, Benedicte Delcoigne, Daniela Di Giuseppe, Lennart Jacobsson, Merete Lund Hetland, Adrian Ciurea, Lucie Nekvindova, Florenzo Iannone, Nurullah Akkoc, Tuulikki Sokka-Isler, Karen Minde Fagerli, Maria Jose Santos, Catalin Codreanu, Manuel Pombo-Suarez, Ziga Rotar, Bjorn Gudbjornsson, Irene Van der Horst-Bruinsma, Anne Gitte Loft, Burkhard Moeller, Herman Mann, Fabrizio Conti, Gozde Yildirim Cetin, Heikki Relas, Brigitte Michelsen, Pedro Avila Ribeiro, Ruxandra Ionescu, Carlos Sanchez-Piedra, Matija Tomsic, Arni Jon Geirsson, Johan Askling, Bente Glintborg, Ulf Lindstroem
Summary: This multicenter study of axSpA patients found similar one-year treatment outcomes between TNFi monotherapy and csDMARD co-therapy. Heterogeneity across countries limited the identification of specific subgroups, such as peripheral arthritis, that may benefit from co-therapy.
Article
Medicine, General & Internal
Eon Jeong Nam, Won Kee Lee
Summary: This study examined the likelihood of achieving clinical remission in patients with ankylosing spondylitis receiving tumor necrosis factor-alpha inhibitors. Age and improvement in disease activity markers within three months were identified as independent predictors of achieving clinical remission.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Clinical Neurology
Naiwen Hu, Xi Chen, Shanjuan Wang, Gangying Yuan, Qinqin Wang, Huae Shu, Hongsheng Sun
Summary: The polymorphisms of the TNF gene are associated with ankylosing spondylitis susceptibility, with certain gene variations showing significance in different ethnic populations. However, the results may vary between subgroups and the overall population.
EUROPEAN SPINE JOURNAL
(2021)
Review
Rheumatology
Francisco Airton Castro Rocha, Ana Carolina Matias Dinelly Pinto, Jailson Rodrigues Lopes, Atul Deodhar
Summary: TNFi is effective in preventing hip damage in AS patients, delaying the need for hip arthroplasty. Prompt initiation of TNFi is crucial for suspected hip involvement in AS patients.
CLINICAL RHEUMATOLOGY
(2021)
Article
Immunology
Jiayong Ou, Min Xiao, Yefei Huang, Liudan Tu, Zena Chen, Shuangyan Cao, Qiujing Wei, Jieruo Gu
Summary: This study investigated the systemic metabolic shifts associated with AS and TNF inhibitors treatment using LC-MS technology. A diagnostic panel comprising five metabolites was developed, capable of distinguishing HCs from AS with high accuracy. The study also revealed the metabolic pathways involved in AS and the effects of TNF inhibitors therapy on metabolism.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Rheumatology
Sizheng Steven Zhao, Gareth T. Jones, Gary J. Macfarlane, David M. Hughes, Robert J. Moots, Nicola J. Goodson
Summary: The study found that patients with multiple comorbidities in axSpA had poorer treatment outcomes when receiving TNFi therapy, with increased risk of treatment discontinuation, and poorer improvements in function and quality of life.
Article
Medicine, General & Internal
Polina Kagan, Noy Horesh, Howard Amital, Avishai M. M. Tsur, Abdulla Watad, Arnon D. D. Cohen, Niv Ben-Shabat
Summary: AS patients in Israel have a higher overall risk of cancer compared to controls, especially for solid malignancies, CNS, kidney, and malignancy of unknown primary. Older age, comorbidity of diabetes and IBD, and treatment with DMARDs were associated with a higher risk of solid malignancies within AS patients, while NSAIDs treatment alone had a protective effect.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Rheumatology
Kalliopi Klavdianou, Styliani Tsiami, Xenofon Baraliakos
Summary: Axial SpA is a rheumatic disease characterized by inflammation leading to bone formation and functional impairment. While TNF-alpha and IL-17 have shown efficacy as therapeutic targets in axSpA, clinical trials of anti-IL-23 monoclonal antibodies have yielded negative results, suggesting the existence of an IL-23 independent pathway. The Janus kinase (JAK) pathway is also a potential therapeutic target for further research in improving understanding and management of SpA pathogenesis.
Review
Pharmacology & Pharmacy
Leticia Garcia-Montoya, Paul Emery
Summary: TNFi have shown good efficacy in disease modification in AS. They provide short-term and long-term improvements in all aspects of disease activity as well as physical function in AS patients. Despite the availability of new drugs in the market, TNFi remains the preferred treatment for AS and the best alternative when NSAIDs are no longer suitable.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2021)
Article
Cell Biology
Yongyu Chen, Jing Lei, Song He
Summary: Evidence suggests a connection between m(6)A modification and immune infiltration in IBD. The study identified decreased expression of IGF2BP1 and IGF2BP2 in CD tissues, and decreased expression of IGF2BP2 in UC tissues. It also found associations between different m(6)A clusters and specific immune cell types in the intestinal mucosa.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Medicine, General & Internal
Qing Luo, Yongqin Guo, Qiuyun Xiao, Biqi Fu, Lu Zhang, Yang Guo, Zikun Huang, Junming Li
Summary: This study found that mRNA expression of YTHDF2 in PBMC may be involved in the pathogenesis of AS and a predictive model based on a combination of mRNA YTHDF2 and SII acts as a marker for diagnosis and progression of diseases.
FRONTIERS IN MEDICINE
(2022)
Review
Medicine, General & Internal
Xinzhe Feng, Junjie Qiao, Weidong Xu
Summary: Ankylosing spondylitis (AS) is a rheumatic bone and joint disease characterized by inflammation, erosion, and pathological bone formation. Mesenchymal stem cells (MSCs) play a crucial role in immune regulation and bone formation. However, factors like genetic background, internal environment, infection, and mechanical forces can alter the immune regulation and osteogenic capacity of MSCs in AS. This review analyzes the effects of these factors on MSCs and discusses the potential of MSCs in treating AS, providing insights for further research on inflammation and ectopic ossification.
POSTGRADUATE MEDICAL JOURNAL
(2023)